Laboratory Markers and Germ Cell Tumors

REFERENCES

• International Union Against Cancer, Sobin LH, Wittekind C. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss, 1997.
   Google Scholar
• International Union of Biochemistry and Molecular Biology. Enzyme nomenclature: Recommendations (1992) of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology on the nomenclature and classification of enzymes prepared for IUBMB by Edwin C. Webb. San Diego: Academic Press, 1992.
   Google Scholar
• Jones WG, Appleyard I, Harnden JK, Eds. Germ cell tumours IV. The proceedings of the Fourth Germ Cell Tumour Conference. Leeds. November 1997. London: John Libbey, 1998.
   Google Scholar
• Rajpert De Meyts E, Grigor KM, Skakkebaek NE, Eds. Neoplastic transformation of testicular germ cells. Copenhagen: Munksgaard, 1998.
   Google Scholar
• Jones WG, Harnden P, Appleyard I, Eds. Germ cell tumours III. London: Pergamon Press, 1994.
   Google Scholar
• Rorth M, Daugaard G. Observation and expectant management for low-stage seminoma and nonseminoma. In: Vogelzang N, Scardino P, Shipley W, Coffey S, Eds. Comprehensive textbook of genitourinary oncology. Pp. 1016-21. Baltimore: Williams & Wilkins, 1996.
   Google Scholar
• Peckham M, Ed. The management of testicular tumours. London: Edward Arnold. 1981.
   Google Scholar
• Oosterhuis JW, Walt H, Damjanov I, Eds. Pathobiology of human germ cell neoplasia. Berlin: Springer-Verlag, 1991.
   Google Scholar
• Harnden P, Joffe JK, Jones WG, Eds. Germ cell tumours V. The proceedings of the Fifth Germ Cell Tumour Conference Devonshire Hall, University of Leeds, 13th to 15th September 2001. London: Springer-Verlag, 2002.
   Google Scholar
• Anderson CK, Jones WG, Milford Ward A, Eds. Germ cell tumours. London: Taylor & Francis, 1981.
   Google Scholar
• Jones WG, Milford Ward A, Anderson CK, Eds. Germ cell tumours II. Pergamon Press, 1986.
   Google Scholar
• Rorth M, Grigor KM, Daugaard G, Giwercman A, et al, Eds. Carcinoma-in-situ and cancer of the testis. Biology and treatment. Oxford: Blackwell Scientific, 1987.
   Google Scholar
• Horwich A, Ed. Testicular cancer. Investigation and management. London: Chapman & Hall, 1991.
   Google Scholar
• Jacobsen GK, Talerman A. Atlas of germ cell tumours. Copenhagen: Munksgaard, 1989.
   Google Scholar
• von der Maase H, Engelholm SA, Rorth M, et al. Non-seminomatous testicular germ cell tumours in Denmark 1976-1980. Results of treatment. Acta Radiol Oncol 1984; 23: 255–61.
   PubMed Web of Science ®Google Scholar
• Mann K, Saller B, Hoerman R. Clinical use of HCG and hCG beta determinations. Scand J Clin Lab Invest Suppl 1993; 53(Suppl. 216): 97–104.
   Google Scholar
• Mostofi FK, Sesterhenn IA. International classification of tumours. Histological typing of testis tumors. 2nd ed. Berlin: Springer-Verlag, 1998.
   Google Scholar
• Coupland CA, Chilvers CE, Pike MC, et al. Differences in the aetiology of testicular cancer by histological tumour type. In: Jones WG, Appleyard I, Harnden P, and Joffe JK, Eds. Germ cell tumours IV. The proceedings of the Fourth Germ Cell Tumour Conference. Leeds. November 1997. Pp. 9-16. London: John Libbey, 1998.
   Google Scholar
• de Jong B, van Echten J, Looijenga LH, et al. Cytogenetics of the progression of adult testicular germ cell tumors. Cytogenet Cell Genet 1997; 95: 88–95.
   Google Scholar
• Jacobsen GK, Barlebo H, Schultz HP, et al. Testicular germ cell tumours in Denmark 19761980. Pathology of 1058 consecutive cases. Acta Radiol Oncol 1984; 23: 239–47.
   PubMed Web of Science ®Google Scholar
• Norgaard Pedersen B, Schultz HP, Arends J, et al. Tumour markers in testicular germ cell tumours. Five-year experience from the DATECA Study 1976-1980. Acta Radiol Oncol 1984; 23: 287–94.
   PubMedGoogle Scholar
• von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchiectomy for seminoma of the testis. Eur J Cancer 1993; 29A: 1931–4.
   PubMedGoogle Scholar
• Jacobsen GK, Rorth M, Osterlind K, et al. Histopathological features in stage I non-seminomatous testicular germ cell tumours correlated to relapse. Danish Testicular Cancer Study Group. APMIS 1990; 98: 377–82.
   PubMed Web of Science ®Google Scholar
• Schultz HP, von der Maase H, Rorth M, et al. Testicular seminoma in Denmark 1976-1980. Results and treatment. Acta Radiol Oncol 1984; 23: 263–70.
   PubMed Web of Science ®Google Scholar
• Oliver RT. Clues from natural history and results of treatment supporting the monoclonal origin of germ cell tumours. Cancer Surv 1990; 9: 333–68.
   PubMedGoogle Scholar
• Mostofi FK, Sobin LH. International histological classification of tumours No. 16. Histological typing of testis tumours. Geneva: World Health Organization, 1977.
   Google Scholar
• Engeland A, Haldorsen T, Tretli S, et al. Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010 on the basis of relative survival analysis. A collaboratuive study of the five Nordic Cancer Registries. APMIS Denmark: Munksgaard. 1995.
   Google Scholar
• Schultz, HP, Arends, J, Barlebo, H, et al. Testicular carcinoma in Denmark 1976-1980. Stage and selected clinical parameters at presentation. Acta Radiol Oncol 1984; 23: 249–253.
   PubMed Web of Science ®Google Scholar
• Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304–15.
   PubMed Web of Science ®Google Scholar
• Steele GS, Richie JP, Stewart AK, et al. The National Cancer Base report on patterns of care for testicular carcinoma, 1985-1996. Cancer 1999; 86: 2171–83.
   Google Scholar
• Peckham MJ, Barret A, Liew KH, et al. The treatment of metastatic germ cell testicular tumours with bleomycin, etoposide and cis-platin (BEP). Br J Cancer 1983; 47: 613–9.
   PubMed Web of Science ®Google Scholar
• Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987; 316: 1435–40.
   PubMed Web of Science ®Google Scholar
• Samuels ML, Holoye PY, Johnson DE. Bleomycin combination chemotherapy in the management of testicular neoplasia. Cancer 1975; 36: 318–26.
   PubMed Web of Science ®Google Scholar
• Einhorn L, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 1977; 87: 293–8.
   PubMed Web of Science ®Google Scholar
• Prow DM. Germ cell tumors: staging, prognosis, and outcome. Sem Urol Oncol 1998; 16: 8293.
   Google Scholar
• TNM classification of malignant tumours. 3rd ed. Geneva: International Union Against Cancer, 1978.
   Google Scholar
• International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification. A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594–603.
   PubMed Web of Science ®Google Scholar
• Klavins JV. Tumor markers, clinical and laboratory studies. New York: Alan R Liss, 1985.
   Google Scholar
• Garrett CT, Sell S. Cellular cancer markers. Totowa, New Jersey: Humana Press, 1995.
   Google Scholar
• Aubry F, Satie AP, Rioux Leclercq N, et al. MAGE-4, a germ cell specific marker, is expressed differentially in testicular tumors. Cancer 2001; 92: 2778–85.
   PubMed Web of Science ®Google Scholar
• von Eyben FE. Biochemical markers in advanced testicular germ cell tumors: serum lactate dehydrogenase, urinary chorionic gonadotropin and total urinary estrogens. Cancer 1978; 41: 648–52.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Jacobsen GK, Pedersen H, et al. Multivariate analysis of risk factors in patients with metastatic testicular germ cell tumors treated with vinblastine and bleomycin. Invasion Metastasis 1982; 2: 125–35.
   PubMedGoogle Scholar
• von Eyben FE. Lactate dehydrogenase and its isoenzymes in testicular germ cell tumors: an overview. Oncodev Biol Med 1983; 3: 395–414.
   Google Scholar
• Harper M, Dugaiczyk A. Linkage of the evolutionarily related serum albumin and alfa-fetoprotein genes within q11-12 of human chromosome 4. Am J Hum Genet 1983; 35: 56572.
   Google Scholar
• Seppala M, Ruoslahti E. Alpha-fetoprotein in normal and pregnancy sera. Lancet 1972; I: 375–6.
   Google Scholar
• Norgaard Pedersen B, Raghavan D. Germ cell tumours: A collaboratory review. Oncodev Biol Med 1980; 1: 327–58.
   Google Scholar
• Klepp O, Olasson AM, Henrickson H, et al. Prognostic factors in clinically stage I nonseminomatous germ cell tumors of the testis. Multivariate analysis of a prospective multicenter study. J Clin Oncol 1990; 8: 509–18.
   PubMed Web of Science ®Google Scholar
• Policastro PF, Daniels-McQueen S, Carle G, Boime I. A map of the hCG beta — LH beta gene cluster. J Biol Chem 1986; 251: 5907–16.
   Google Scholar
• Jameson JL, Lindell CM. Isolation and characterization of the human chorionic gonadotropin beta subunit (CG beta) gene cluster: regulation of a transcriptionally active CG beta gene by cyclic AMP. Mol Cell Biol 1988; 8: 5100–7.
   PubMedGoogle Scholar
• Saller B, Clara R, Spottl G, Siddle K, et al. Testicular cancer secretes intact human chorionic gonadotropin (hCG) and its free beta-subunit: evidence that hCG (+hCG-beta) assays are the most reliable in diagnosis and follow-up. Clin Chem 1990; 36: 234–9.
   PubMedGoogle Scholar
• Madersbacher S, Klieber R, Mann K, et al. Free alpha-subunit, free beta-subunit of human chorionic gonadotropin (hCG) and intact hCG in sera of healthy individuals and testicular cancer patients. Clin Chem 1992; 38: 370–6.
   PubMed Web of Science ®Google Scholar
• Lebo RV, Cheung MC, Bruce BD, et al. Mapping parathyroid hormone, beta-globin, insulin, and LDH-A genes within the human chromosome 11 short arm by spot blotting sorted chromosomes. Hum Genet 1985; 69: 316–20.
   PubMedGoogle Scholar
• Graig JW, McBride OW. Report of the committee on the genetic constitution of chromosome 12. Cytogen Cell Genet 1991; 58: 555–79.
   Google Scholar
• Sudo K, Maekawa M, Kanno T, et al. Premature termination mutations in two patients with deficiency of lactate dehydrogenase H(B) subunit. Clin Chem 1994; 40: 1567–70.
   PubMedGoogle Scholar
• Maekawa M, Sudo K, Kanno T, Li SS. Molecular characterization of genetic mutation in human lactate dehydrogenase-A (M) deficiency. Biochem Biophys Res Commun 1990; 168: 677–82.
   PubMedGoogle Scholar
• Kristensen SR. A critical appraisal of the association between energy charge and cell damage. Biochim Biophys Acta 1989; 1012: 272–8.
   PubMed Web of Science ®Google Scholar
• Zondag HA. The 1963 Fiske essay — enzyme activity in dysgerminoma and seminoma. A study of lactic dehydrogenase isoenzymes in malignant diseases. Rhode Island Med J 1964; 47: 273–81.
   PubMedGoogle Scholar
• Zondag HA. Activity of lactate dehydrogenase in patients with malignant tumours of testis and ovary. In: Vandendriesche L, Ed. West-European symposia on clinical chemistry. Pp. 120-9. Amsterdam: Elsevier, 1965.
   Google Scholar
• Chatterley S, Sun T, Lien Y. Diagnostic value of lactate dehydrogenase isoenzymes in cerebrospinal fluid. J Clin Lab Anal 1991; 5: 168–74.
   PubMedGoogle Scholar
• Nishikawa A, Tanaka T, Takeuchi T, et al. The diagnostic significance of lactate dehydrogenase isoenzymes in urinary cytology. Br J Cancer 1991; 63: 819–21.
   PubMedGoogle Scholar
• von Eyben FE, Skude G, Fossa SD, et al. Serum lactate dehydrogenase (S-LDH) and S-LDH isoenzymes in patients with testicular germ cell tumors. Mol Gen Genet 1983; 189: 326–33.
   PubMedGoogle Scholar
• Tucker DF, Oliver RT, Ellard GA, et al. Testicular tumour marker applications of monoclonal antibodies to placental-like alkaline phosphatase. In: Jones WG, Milford Ward A, Anderson CK, Eds. Germ cell tumours II. Pp. 139-45. Oxford: Pergamon Press, 1986.
   Google Scholar
• Maekawa M. Lactate dehydrogenase isoenzymes. J Chromatogr 1988; 429: 373–98.
   PubMedGoogle Scholar
• Usategui Gomez M, Wicks RW, Warshaw M. Immunochemical determination of the heart isoenzyme of lactate dehydrogenase (LDH1) in human serum. Clin Chem 1979; 25: 729–34.
   PubMedGoogle Scholar
• Committee on Enzymes of the Scandinavian Society for Clinical Chemistry and Clinical Physiology. Recommended methods for determination of four enzymes in blood. Scand J Clin Lab Invest 1974; 33: 291–306.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Blaabjerg O, Petersen PH, et al. Serum lactate dehydrogenase isoenzyme 1 as a marker of testicular germ cell tumor. J Urol 1988; 140: 986–90.
   PubMedGoogle Scholar
• von Eyben FE, Madsen EL, Blaabjerg O, et al. Serum lactate dehydrogenase isoenzyme 1 in patients with seminoma stage I followed with surveillance. Acta Oncol 2002; 41: 77–83.
   PubMedGoogle Scholar
• von Eyben FE, Mirza MR, Blaabjerg O, et al. Ovarian germ cell tumors and lactate dehydro-genase isoenzyme 1. J Tumor Marker Oncol 2002; 17: 5–11.
   Google Scholar
• von Eyben FE, Madsen EL, Blaabjerg O, et al. Serum lactate dehydrogenase isoenzyme 1. An early indicator of relapse in patients with testicular germ cell tumors. Acta Oncol 1995; 34: 925–9.
   PubMedGoogle Scholar
• von Eyben FE, Madsen EL, Blaabjerg O, et al. Serum lactate dehydrogenase isoenzyme 1 and relapse in patients with nonseminomatous testicular germ cell tumors clinical stage I. Acta Oncol 2001; 40: 536–40.
   PubMedGoogle Scholar
• von Eyben FE, Liu FJ, Amato RJ, Fritsche HA. Lactate dehydrogenase (LD) isoenzyme 1 is the most important LD isoenzyme in patients with testicular germ cell tumor. Acta Oncol 2000; 39: 509–17.
   PubMedGoogle Scholar
• von Eyben FE, Madsen EL, Liu F, et al. Serum lactate dehydrogenase isoenzyme 1 as a prognostic predictor for metastatic testicular germ cell tumours. Br J Cancer 2000; 83: 12569.
   Google Scholar
• von Eyben FE, Blaabjerg O, Petersen PH, et al. Serum lactate dehydrogenase isoenzyme 1 and prediction of death in patients with metastatic testicular germ cell tumors. Clin Chem Lab Med 2001; 39: 38–44.
   PubMedGoogle Scholar
• von Eyben FE, Petersen PH, Blaabjerg O, et al. Correcting for contamination from hemolysis in measurements of lactate dehydrogenase isoenzyme 1 in serum from patients with testicular germ cell tumors. Clin Chem 1993; 39: 2199.
   PubMedGoogle Scholar
• von Eyben FE, Petersen PH, Blaabjerg O, et al. Analytical bias by contamination from hemolysis in determination of lactate dehydrogenase isoenzyme 1 in patients with testis germ cell tumors. Ups J Med Sci 1993; 98: 293–8.
   PubMed Web of Science ®Google Scholar
• Harboe M. A method for determination of hemoglobin in plasma by near-violet spectropho-tometry. Scand J Clin Lab Invest 1959; 11: 66–7.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Blaabjerg O, Petersen PH, et al. Lactate dehydrogenase isoenzyme 1 in testicular germ cell tumors. In: Oosterhuis JW, Walt H, Damjanov I, Eds. Pathobiology of human germ cell neoplasia. Pp. 85-92. Berlin: Springer Verlag, 1991.
   Google Scholar
• Christensen M. Clinical test evaluation. Basic concepts. Scand J Clin Lab Invest 1992; 52(Suppl. 208): 13–29.
   Google Scholar
• Bais R, Philcox M. Approved recommendation on IFCC methods for the measurement of catalytic concentration of enzymes. Part 8. IFCC method for lactate dehydrogenase (L-Lactate: NAD+ Oxidoreductase, EC 1.1.1.27). Eur J Clin Chem Clin Biochem 1994; 32: 639–55.
   PubMedGoogle Scholar
• Petersen PH, Gowans EMS, Blaabjerg O. Analytical goals for the estimation of non-gaussian reference intervals. Scand J Clin Lab Invest 1989; 49: 727–37.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Petersen PH, Blaabjerg O, et al. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin Chem Lab Med 1999; 37: 553–61.
   PubMedGoogle Scholar
• Petersen PH, Blaabjerg O, Irjala K, et al. Elements of analytical quality. Ups J Med Sci 1994; 99: 209–30.
   Google Scholar
• Pfleiderer G, Wachsmuth ED. Age and function dependent differentiation of lactate dehydro-genase of human organs dependent on age and function (Alters-und funktionsabhangige Differenzierung der Laktatdehydrogenase menschlischer Organe). Biochemistry 1961; 334: 185–198.
   Google Scholar
• Fossa A, Fossa SD. Serum lactate dehydrogenase and human chorionic gonadotropin in seminoma. Br J Urol 1989; 63: 408–15.
   PubMedGoogle Scholar
• Taylor RE, Duncan W, Horn DB. Lactate dehydrogenase as a marker for testicular germ-cell tumours. Eur J Cancer 1986; 22: 647–53.
   Google Scholar
• Hida S, Nishimura K, Nishio Y, et al. VAB-6 chemotherapy causes spurious elevation of alpha-fetoprotein associated with liver dysfunctions. Urol Int 1991; 46: 1–5.
   PubMedGoogle Scholar
• Germa JR, Llanos M, Tabernero JM, Mora J. False elevations of alpha-fetoprotein associated with liver dysfunction in germ cell tumors. Cancer 1993; 72: 2491–4.
   PubMed Web of Science ®Google Scholar
• Oosterom R, Stoter G. Standardizing human chorionic gondatropin measurements in serum of testicular cancer patients. Clin Chem 1992; 38: 601–2.
   PubMedGoogle Scholar
• von Eyben FE, Skude G, Krabbe S. Serum lactate dehydrogenase and its isoenzymes in men with maldescended testes. J Urol 1982; 128: 1195–7.
   PubMedGoogle Scholar
• von Eyben F, Krabbe S, Skakkebaek NE. Alpha-foetoprotein and human chorionic gonadot-ropin in men with maldescended testes. Br J Cancer 1980; 42: 156–7.
   PubMedGoogle Scholar
• Jaeschke R, Guyatt G, Sackett D. User's guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? JAMA 1994; 271: 38991.
   Google Scholar
• Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test research. Getting better but still not good. JAMA 1995; 274: 645–51.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Skude G, Trope C, et al. Lactate dehydrogenase isoenzyme 1 (LDH-1) in athymic mice with xenografts of a human testicular germ cell tumor. Mol Gen Genet 1982; 186: 427–31.
   PubMedGoogle Scholar
• Rorth M, Jacobsen GK, von der Maase H, et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. J Clin Oncol 1991; 9: 1543–8.
   PubMedGoogle Scholar
• von Eyben FE, Blaabjerg O, Madsen EL, et al. Serum lactate dehydrogenase isoenzyme 1 and tumour volume are indicators of response to treatment and predictors of prognosis in meta-static testicular germ cell tumours. Eur J Cancer 1992; 238: 410–5.
   Google Scholar
• Gill PG, Abbott R, Jones AM, et al. The management of metastatic testicular germ cell tumours and the clinical utility of lactate dehydrogenase estimations. Aust NZ J Surg 1985; 55: 133–40.
   PubMedGoogle Scholar
• Sugawara T, Furuhata T, Ogawa K, et al. A clinical study of testicular tumors — usefulness of seurm lactic dehydrogenase. Jpn J Urol 1986; 77: 948–52.
   PubMedGoogle Scholar
• von Eyben FE. A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin Biochem 2001; 34: 441–54.
   PubMed Web of Science ®Google Scholar
• Cullen M. Management of stage I nonseminoma: surveillance and chemotherapy. In: Horwich A, Ed. Testicular Cancer: Investigation and management. Pp. 149-66. London: Chapman & Hall, 1991.
   Google Scholar
• World Health Organization. WHO handbook of reporting results of cancer treatment. Geneva: World Health Organization, 1979.
   Google Scholar
• Bajorin DF, Mazumdar M, Meyers M, et al. Metastatic germ cell tumors: modeling for response to chemotherapy. J Clin Oncol 1998; 16: 707–15.
   PubMedGoogle Scholar
• Klepp O. Serum tumour markers in testicular and extragonadal germ cell malignancies. Scand J Clin Lab Invest Suppl. 1991; 206: 28–41.
   PubMedGoogle Scholar
• Vogelzang NJ. Prognostic factors in metastatic testicular cancer. Int J Androl 1987; 10: 225–37.
   PubMedGoogle Scholar
• von Eyben, FE, Madsen, EL, Fritsche H, et al. A new model for testicular germ cell tumours. APMIS 2003. 111: 100–5.
   PubMedGoogle Scholar
• Fossa SD, Collette L, Aaronson N, et al. Quality of life in patients with good prognosis metastatic germ cell tumours: comparison of four chemotherapy schedules (EORTC 3094/ MRC TE20). In: Harnden P, Joffe JK, Jones WC, Eds. Germ cell tumours V. The proceedings of the Fifth Germ Cell Tumour Conference Devonshire Hall, University of Leeds,13th to 15 th September 2001. Pp. 183-95. London: Springer-Verlag, 2002.
   Google Scholar
• von Eyben FE, Madsen EL. Serum lactate dehydrogenase isoenzyme 1 as predictor of tumour-associated death in patients with testicular germ cell tumours. Andrologia 1997; 29: 137–40.
   PubMedGoogle Scholar
• Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors. Cancer Res 1998; 58: 4260–3.
   PubMed Web of Science ®Google Scholar
• Gerl A, Lamerz R, Clemm C, et al. Tumour marker half-life as a test of prognosis in metastatic nonseminomatous germ cell tumours: a critical appraisal. In: Jones WG, Appleyard I, Harnden P, Joffe JK, Eds. Germ Cell Tumours IV: The proceedings of the Fourth Germ Cell Tumour Conference. Leeds. November 1997. Pp. 99-104. London: John Libbey, 1998.
   Google Scholar
• Vogelzang NJ, Lange PJ, Goldman A, et al. Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 1982; 42: 4855–61.
   PubMed Web of Science ®Google Scholar
• Trigo JM, Tabernero JM, Pas Ares L, et al. Tumor markers at the time of recurrence in patients with germ cell tumors. Cancer 2000; 88: 162–8.
   PubMed Web of Science ®Google Scholar
• Scheulen ME, Pfeiffer R, Kropfl D, et al. The significance of the tumor markers alpha1-fetoprotein and beta-hCG for the staging and monitoring of nonseminomatous testicular germ cell tumors (Die Bedeutung der Tumormarker Alpha1-fetoprotein und Beta-HCG bei der Stadieinteilung und Verlaufkontrolle nicht-seminomatoser Hodentumoren). Therapiewoche 1982; 323: 525–31.
   Google Scholar
• Motzer RJ, Geller N, Bosl GJ. The effect of a 7-day delay in chemotherapy cycles on complete response and event-free survival in good-risk disseminated germ cell tumor patients. Cancer 1990; 66: 857–61.
   PubMedGoogle Scholar
• Petersen PM, Giwercman A, Daugaard G, et al. Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 2002; 20: 1537–43.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Horwich A, Russel JM, et al. Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicu-lar Tumor Working Group. J Clin Oncol 1999; 17: 1146–54.
   PubMed Web of Science ®Google Scholar
• Dieckmann KP, Bruggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 2000; 55: 102–6.
   PubMed Web of Science ®Google Scholar
• Pont J, Holtl W, Kosak D, et al. Risk-adapted treatment choice in stage I nonseminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor: a prospective trial. J Clin Oncol 1990; 8: 16–20.
   PubMed Web of Science ®Google Scholar
• McCaffrey JA, Bajorin DF. Therapy for good risk germ cell tumors. Semin Oncol 1998; 25: 186–93.
   PubMedGoogle Scholar
• de Wit R, Roberts T, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3-or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19: 1629–40.
   PubMed Web of Science ®Google Scholar
• Toner GC, Stockler MR, Boyer MJ, et al. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 2001; 357: 739–45.
   PubMed Web of Science ®Google Scholar
• Toner GC, Motzer RJ. Poor prognosis germ cell tumors: current status and future directions. Semin Oncol 1998; 25: 194–202.
   PubMedGoogle Scholar
• Flechon A, Biron P, Droz JP. High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: the French experience. Int J Cancer 1999; 83: 844–7.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346–51.
   PubMed Web of Science ®Google Scholar
• Hinton S, Catalano P, Einhorn LH, et al. Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2002; 20: 1859–63.
   PubMed Web of Science ®Google Scholar
• Kawai M, Kano T, Kikkawa F, et al. Seven tumor markers in benign and malignant germ cell tumors of the ovary. Gynecol Oncol 1992; 45: 248–53.
   PubMedGoogle Scholar
• Newlands ES, Holden L, Bagshawe KD. Tumour markers and POMB/ACE chemotherapy in the management of ovarian germ cell tumours (GCTs). Int J Biol Markers 1988; 3: 18592.
   Google Scholar
• van Echten J, van Doorn LC, van der Linden HC, et al. Cytogenetics of a malignant ovarian germ-cell tumor. Int J Cancer 1998; 77: 217–8.
   PubMedGoogle Scholar
• Zinkham WH, Blanco A, Kupchyk L. Lactate dehydrogenase in testis: dissociation and recombination of subunits. Science 1963; 142: 1303–4.
   PubMedGoogle Scholar
• Orlando C, Casano R, Caldini AL, et al. Measurement of seminal LDH-X and transferrrin in normal and infertile men. J Androl 1988; 9: 220–3.
   PubMedGoogle Scholar
• Edwards Y, West L, van Heyningen V, et al. Regional localization of the sperm-specific lactate dehydrogenase, LDH-C, gene on human chromosome 11. Am J Hum Genet 1989; 53: 215–9.
   Google Scholar
• Thomas K, Del Mazo J, Eversole P, et al. Developmental regulation of expression of the lactate dehydrogenase (LDH) multigene family during mouse spermatogenesis. Development 1990; 109: 483–93.
   PubMedGoogle Scholar
• Alcivar AA, Trasler JM, Hake IE, et al. DNA methylation and expression of the genes coding for lactate dehydrogenase A and C during rodent spermatogenesis. Biol Reprod 1991; 44: 52735.
   Google Scholar
• Bonny C, Cooker LA, Goldberg E. Deoxyribonucleic acid-protein interactions and expression of the human testis-specific lactate dehydrogenase promoter: transcription factor Sp1 plays a major role. Biol Reprod 1998; 58: 754–9.
   PubMedGoogle Scholar
• Bonny C, Goldberg E. The CpG-rich promoter and human LDH-C is differentially methylated in expressing and nonexpressing tissues. Dev Genet 1995; 16: 210–7.
   PubMedGoogle Scholar
• Skude G, von Eyben FE, Kristiansen P. Additional lactate dehydrogenase (LDH) isoenzymes in normal testis and spermatozoa of adult man. Mol Gen Genet 1984; 198: 172–4.
   PubMedGoogle Scholar
• Eliasson R, Virji N. LDH-C4 in human seminal plasma and its relationship to testicular function. II Clinical aspects. Int J Androl 1985; 8: 208–14.
   Google Scholar
• Vogelzang NJ, Lange PH, Goldberg E. Absence of sperm-specific lactate dehydrogenase-X in patients with testis cancer. Oncodev Biol Med 1982; 3: 269–72.
   PubMedGoogle Scholar
• Liu F, Fritsche H, Trujillo JM, Samuels ML. Serum lactate dehydrogenase isoenzyme 1 in patients with advanced testicular cancer. Am J Clin Pathol 1982; 78: 178–83.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Mikulowski P, Busch C. Microinvasive germ cell tumors of the testis. J Urol 1981; 126: 842–4.
   PubMedGoogle Scholar
• Rorth M, Rajpert De Meyts E, Andersson L, et al. Carcinoma in situ in the testis. Scand J Nephrol Urol Suppl 2000; 205: 166–86.
   Google Scholar
• de Graaff WE, Oosterhuis JW, de Jong B, et al. Ploidy of testicular carcinoma in situ. Lab Invest 1992; 66: 166–8.
   PubMed Web of Science ®Google Scholar
• Castedo SM, de Jong B, Oosterhuis JW, et al. Cytogenetic analysis of ten human seminomas. Cancer Res 1989; 49: 439–43.
   PubMedGoogle Scholar
• Castedo SM, de Jong B, Oosterhuis JW, et al. Chromosomal changes in human primary testicular nonseminomatous germ cell tumors. Cancer Res 1989; 49: 5696–701.
   PubMedGoogle Scholar
• Mertens F, Johansson B, Mitelman F. Isochromosomes in neoplasia. Gene Chromosomes Cancer 1994; 10: 221–30.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Holzik ML. Alpha fetoprotein, tumor histology, and copy number of isochro-mosome i(12p) in testicular germ cell tumors. J Tumor Marker Oncol 2002; 17: 5–11.
   Google Scholar
• Byrialsen A, von Eyben FE, Kristiansen K. Carcinoma in situ of the testis and seminoma express a high protein level of lactate dehydrogenase subunit B but no subunit C. J Tumor Marker Oncol 1998; 13: 79–86.
   Google Scholar
• Starkweather WH, Schoh HK. Some observations on the lactate dehydrogenase of human neoplastic tissue. Biochim Biophys Acta 1962; 62: 440–2.
   PubMedGoogle Scholar
• Sakakibara N, Sakashita S, Koyanagi T. Total LDH activities and LDH isoenzyme patterns in the tissues of testicular tumors. Jpn J Urol 1987; 78: 249–52.
   PubMedGoogle Scholar
• Murakami SS, Said JW. Immunohistochemical localization of lactate dehydrogenase isoenzyme 1 in germ cell tumors of the testis. Am J Clin Pathol 1984; 81: 293–6.
   PubMedGoogle Scholar
• Takeuchi T, Nakayasu M, Hirohashi S, et al. Human endodermal sinus tumour in nude mice and its markers for diagnosis and management. J Clin Pathol 1979; 32: 693–9.
   PubMedGoogle Scholar
• Henderson AR, Ahmad D, McKenzie D. Increased synthesis of lactate dehydrogenase “H” subunit by a malignant tumor. Clin Chem 1974; 20: 1466–9.
   PubMedGoogle Scholar
• Langvad E, Zachariah J, Pindborg JJ. Lactate dehydrogenase isoenzyme patterns in leukoplakia, submucous fibrosis and carcinoma of the oral mucosa in south Indians. APMIS 1970; 78: 509–15.
   Google Scholar
• Takatera H, Nomura T, Itatani H. Differential expression of a human sperm-specific isoenzyme in seminoma cells transplanted in Scid-nu(str) mice. Jpn J Cancer Res 1993; 84: 215–8.
   PubMedGoogle Scholar
• Rethore MO, Kaplan JC, Junien C, et al. Increase of the activity of LDH-B in a boy with 12 trisomy due to malsegregation of a maternal translocation t(12;11)(q12;p11) (Augmentation de l'activite de la LDH-B chez un garcon trisomique 12p par malsegregation d'une translocation maternelle t(12;11)(q(12;p11)). Ann Genet 1975; 18: 81–7.
   PubMedGoogle Scholar
• Steinbach P, Rehder H. Tetrasomy for the short arm of chromosome 12 with accessory isochromosome (+i(12p)) and a marked LDH-B gene dosage effect. Clin Genet 1987; 32: 1–4.
   PubMedGoogle Scholar
• von Eyben FE, de Graaff W, Marrink J, et al. Serum lactate dehydrogenase isoenzyme-1 activity in patients with testicular germ cell tumors correlates with the total number of copies of the short arms of chromosome 12 in the tumor. Mol Gen Genet 1992; 235: 140–6.
   PubMedGoogle Scholar
• Rosenberg C, Schut TB, Mostert M, et al. Chromosomal gains and losses in testicular germ cell tumors of adolescents and adults investigated by a modified comparative genomic hybridization approach. Lab Invest 1999; 79: 1447–51.
   PubMedGoogle Scholar
• Rosenberg C, van Gurp RJ, Geelen E, et al. Overrepresentation of the short arm of chromosome 12 is related to invasive growth of human testicular seminomas and nonseminomas. Oncogene 2000; 19: 5858–62.
   PubMedGoogle Scholar
• Mostert MC, Verkerk AJ, van de Pol M, et al. Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 1998; 16: 2617–27.
   PubMed Web of Science ®Google Scholar
• Mostert MC, van de Pol M, Weghuis DO, et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p-amplicon. Cancer Genet Cytogenet 1996; 89: 146–52.
   PubMedGoogle Scholar
• Roelofs H, Mostert MC, Pompe K, et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 2000; 157: 1155–66.
   PubMed Web of Science ®Google Scholar
• Hesketh R. The oncogene handbook. London: Academic Press, 1994.
   Google Scholar
• Rajpert De Meyts E, Skakkebaek NE. Expression of the c-kit protein product in carcinoma-in-situ and invasive testicular germ cell tumours. Int J Androl 1994; 17: 85–92.
   PubMedGoogle Scholar
• Strohmeyer T, Peter S, Hartmann M, et al. Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res 1991; 51: 1811–6.
   PubMed Web of Science ®Google Scholar
• Strohmeyer T, Reissmann P, Cordon Cardo C, et al. Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 1991; 88: 6662–6.
   PubMed Web of Science ®Google Scholar
• Houldsworth J, Reuter V, Bosl GJ, et al.Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis.Cell Growth Differ 1997; 8: 293–9.
   PubMedGoogle Scholar
• Caricasole AA, van Schaik RH, Zeinstra LM, etal. Human growth-differentiation factor 3 (hGDF3): developmental regulation in human teratocarcinoma cell lines and expression in primary testicular germ cell tumours. Oncogene 1998; 15: 95–103.
   Google Scholar
• Murty VV, Li RG, Houldsworth J, etal. Frequent allelic deletions and loss of expression characterize the DCC gene in male germ cell tumors. Oncogene 1994; 9: 3227–31.
   PubMed Web of Science ®Google Scholar